Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 5, 2017, Pages 1126-1135

  Chen, Mee Yew ^a   Kirkwood, Carl D ^b,c,e   Bines, Julie ^b,c,d   Cowley, Daniel ^b,c   Pavlic, Daniel ^b   Lee, Katherine J ^b,c   Orsini, Francesca ^b   Watts, Emma ^b   Barnes, Graeme ^b,c   Danchin, Margaret ^b,c,d  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e LA TROBE UNIVERSITY   (Australia)

Author keywords

developing countries; efficacy; maternal antibodies; rotavirus vaccines

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MATERNAL ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO; ROTAVIRUS VACCINE; RV3 BB ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; LIVE VACCINE; RV3 ROTAVIRUS VACCINE; VIRUS ANTIBODY;

ADULT; ARTICLE; BREAST MILK; CLINICAL ARTICLE; COLOSTRUM; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE; HUMAN; IMMUNE RESPONSE; LOGISTIC REGRESSION ANALYSIS; MALE; NEW ZEALAND; NEWBORN; ROTAVIRUS INFECTION; SEQUENCE ANALYSIS; SEROCONVERSION; T CELL DEPLETION; UMBILICAL CORD BLOOD; VACCINATION; VIRUS EXCRETION; VIRUS REPLICATION; BLOOD; CLINICAL TRIAL; COST OF ILLNESS; FECES; IMMUNOLOGY; INFANT; PASSIVE IMMUNIZATION; PHASE 2 CLINICAL TRIAL; PREGNANCY; VIROLOGY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; COLOSTRUM; COST OF ILLNESS; FECES; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN A; INFANT; INFANT, NEWBORN; MALE; MILK, HUMAN; NEW ZEALAND; PREGNANCY; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 85019596060     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1274474     Document Type: Article

References (42)

1. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, WHO-coordinated Global Rotavirus Surveillance Network. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes:a systematic review and meta-analysis. Lancet Infect Dis 2012; 12(2):136-41; http://dx.doi.org/10.1016/S1473-3099(11)70253-5
2. World Health Organisation. WHO recommends global use of rotavirus vaccines. WHO Weekly Epidemiological Record 2009; 23:232–236.
3. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Eng J of Med 2006; 354(1):23-33; PMID:16394299; http://dx.doi.org/10.1056/NEJMoa052664
4. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis B, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Eng J Med 2006; 354(1):11-22; PMID:16394298; http://dx.doi.org/10.1056/NEJMoa052434
5. Phua KB, Lim FS, Lau YL, Nelson EAS, Huang LM, Quak SH, Lee BW, Teoh YL, Tang H, Boudville I, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants:randomised, double-blind, controlled study. Vaccine 2009; 27(43):5936-41; PMID:19679216; http://dx.doi.org/10.1016/j.vaccine.2009.07.098
6. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants:randomised, double-blind controlled study. Lancet 2007; 370(9601):1757-63; PMID:18037080; http://dx.doi.org/10.1016/S0140-6736(07)61744-9
7. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Eng J Med 2010; 362(4):289-98; PMID:20107214; http://dx.doi.org/10.1056/NEJMoa0904797
8. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa:a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376(9741):606-14; PMID:20692030; http://dx.doi.org/10.1016/S0140-6736(10)60889-6
9. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TP, Luby SP, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia:a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376(9741):615-23; PMID:20692031; http://dx.doi.org/10.1016/S0140-6736(10)60755-6
10. Field EJ, Vally H, Grimwood K, Lambert SB. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 2010; 126(3):e506-12; PMID:20732946; http://dx.doi.org/10.1542/peds.2010-0443
11. Eberly MD, Gorman GH, Eide MB, Olsen CH, Rajnik M. The effect of rotavirus immunization on rotavirus gastroenteritis hospitalization rates in military dependents. Vaccine 2011; 29(4):650-9; PMID:21129394; http://dx.doi.org/10.1016/j.vaccine.2010.11.041
12. Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010; 125(2):e208-13; PMID:20100757; http://dx.doi.org/10.1542/peds.2009-1246
13. Justino MC, Linhares A, Lanzieri T, Miranda Y, Mascarenhas JD, Abreu E, Guerra SF, Oliveira AS, da Silva VB, Sanchez N, et al. Effectiveness of the monovalent G1P[8]Human rotavirus vaccine against hospitalization for severe G2P[4]rotavirus gastroenteritis in Belem, Brazil. Pediat Infect Dis J 2011; 30(5):396-401; PMID:21150692; http://dx.doi.org/10.1097/INF.0b013e3182055cc2
14. de Palma O, Cruz L, Ramos H, de Baires A, Villatoro N, Pastor D, de Oliveira LH, Kerin T, Bowen M, Gentsch J, et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador:Case-control study. BMJ 2010;340:c2825.
15. Mast TC, Khawaja S, Espinoza F, Paniagua M, Del Carmen LP, Cardellino A, Sánchez E. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua. Pediat Infect Dis J 2011; 30(11):e209-15; PMID:21768920; http://dx.doi.org/10.1097/INF.0b013e31822a8527
16. Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, Gonzalez A, Malespin O, Amador JJ, Umaña J, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301(21):2243-51; PMID:19491186; http://dx.doi.org/10.1001/jama.2009.756
17. Serazin AC, Shackelton LA, Wilson C, Bhan MK. Improving the performance of enteric vaccines in the developing world. Nat Immunol 2010; 11(9):769-73; PMID:20720580; http://dx.doi.org/10.1038/ni0910-769
18. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines:how well will they work where they are needed most? J Infect Dis 2009; 200(Suppl 1):S39-48.
19. Niewiesk S. Maternal antibodies:clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol 2014; 5:446; PMID:25278941; http://dx.doi.org/10.3389/fimmu.2014.00446
20. Edwards KM. Maternal antibodies and infant immune responses to vaccines. Vaccine 2015; 33(47):6469-72; PMID:26256526; http://dx.doi.org/10.1016/j.vaccine.2015.07.085
21. Patel M, Steele AD, Parashar UD. Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines. Vaccine 2012; 30(Supplement 1):A30-A5; http://dx.doi.org/10.1016/j.vaccine.2011.11.093
22. Kirkwood CD. Genetic and antigenic diversity of human rotaviruses:potential impact on vaccination programs. J Infect Dis 2010; 202(Supplement 1):S43-S8; PMID:20684716; http://dx.doi.org/10.1086/653548
23. Chan J, Nirwati H, Triasih R, Bogdanovic-Sakran N, Soenarto Y, Hakimi M, Duke T, Buttery JP, Bines JE, Bishop RF, et al. Maternal antibodies to rotavirus:could they interfere with live rotavirus vaccines in developing countries? Vaccine 2011; 29(6):1242-7; PMID:21147127
24. Moon S-S, Wang Y, Shane AL, Nguyen T, Ray P, Dennehy P, Baek LJ, Parashar U, Glass RI, Jiang B. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediat Infect Dis J 2010; 29(10):919-23; PMID:20442687; http://dx.doi.org/10.1097/INF.0b013e3181e232ea
25. Rongsen-Chandola T, Strand TA, Goyal N, Flem E, Rathore SS, Arya A, Winje BA, Lazarus R, Shanmugasundaram E, Babji S, et al. Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants. Vaccine 2014; 32(Suppl 1):A134-9; http://dx.doi.org/10.1016/j.vaccine.2014.04.078
26. Groome MJ, Moon S-S, Velasquez D, Jones S, Koen A, van Niekerk N, Jiang B, Parashar UD, Madhi SA. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine:a randomized trial in HIV-uninfected infants in Soweto, South Africa. Bull World Health Org 2014; 92(4):238-45; PMID:24700991; http://dx.doi.org/10.2471/BLT.13.128066
27. Ali A, Kazi AM, Cortese MM, Fleming JA, Moon S, Parashar UD, Jiang B, McNeal MM, Steele D, Bhutta Z, et al. Impact of withholding breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine—a randomized trial. PloS One 2015; 10(6):e0127622; PMID:26035743; http://dx.doi.org/10.1371/journal.pone.0127622
28. Bines JE, Danchin M, Jackson P, Handley A, Watts E, Lee KJ, West A, Cowley D, Chen MY, Barnes GL, et al. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy:A randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2015; 15:1389-97; PMID:26318715
29. Milne RJ, Grimwood K. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule. Value in Health 2009; 12(6):888-98; PMID:19490550; http://dx.doi.org/10.1111/j.1524-4733.2009.00534.x
30. Newburg DS, Peterson JA, Ruis-Palacios GM, Matson DO, Morrow AL, Shults J, Guerrero ML, Chaturvedi P, Newburg SO, Scallan CD, et al. Role of human-milk lactadherin in protection against symptomatic rotavirus infection. Lancet 1998; 351(9110):1160; PMID:9643686; http://dx.doi.org/10.1016/S0140-6736(97)10322-1
31. Yolken RH, Peterson JA, Vonderfecht SL, Fouts ET, Midthun K, Newburg DS. Human milk mucin inhibits rotavirus replication and prevents experimental gastroenteritis. J Clin Invest 1992; 90(5):1984-91; PMID:1331178; http://dx.doi.org/10.1172/JCI116078
32. Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses:review of hypotheses and definition of main determinants. Vaccine 2003; 21(24):3406-12; PMID:12850349; http://dx.doi.org/10.1016/S0264-410X(03)00342-6
33. Nguyen TV, Yuan L, Azevedo MS, Jeong K-I, Gonzalez AM, Iosef C, Lovgren-Bengtsson K, Morein B, Lewis P, Saif LJ. Low titer maternal antibodies can both enhance and suppress B cell responses to a combined live attenuated human rotavirus and VLP-ISCOM vaccine. Vaccine 2006; 24(13):2302-16; PMID:16361002; http://dx.doi.org/10.1016/j.vaccine.2005.11.043
34. Graham KL, Halasz P, Tan Y, Hewish MJ, Takada Y, Mackow ER, Robinson MK, Coulson BS. Integrin-using rotaviruses bind α2β1 integrin α2 I domain via VP4 DGE sequence and recognize αXβ2 and αVβ3 by using VP7 during cell entry. J Virol 2003; 77(18):9969-78; PMID:12941907; http://dx.doi.org/10.1128/JVI.77.18.9969-9978.2003
35. Van Den Driessche M, Peeters K, Marien P, Ghoos Y, Devlieger H, Veereman-Wauters G. Gastric emptying in formula-fed and breast-fed infants measured with the 13C-octanoic acid breath test. J Pediat Gastroenterol Nutrit 1999; 29(1):46-51; PMID:10400103; http://dx.doi.org/10.1097/00005176-199907000-00013
36. Appaiahgari MB, Glass R, Singh S, Taneja S, Rongsen-Chandola T, Bhandari N, Mishra S, Vrati S. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine 2014; 32(6):651-6; PMID:24374502; http://dx.doi.org/10.1016/j.vaccine.2013.12.017
37. Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U. A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis 2013; 208(2):284-94; PMID:23596320; http://dx.doi.org/10.1093/infdis/jit166
38. Pichichero ME. Effect of breast-feeding on oral rhesus rotavirus vaccine seroconversion:a metaanalysis. J Infect Dis 1990; 162(3):753-5; PMID:2167344; http://dx.doi.org/10.1093/infdis/162.3.753
39. Rennels MB. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J Infect Dis 1996; 174(Suppl 1):S107-11; http://dx.doi.org/10.1093/infdis/174.Supplement_1.S107
40. Bishop RF, Cipriani E, Lund JS, Barnes GL, Hosking CS. Estimation of rotavirus immunoglobulin G antibodies in human serum samples by enzyme-linked immunosorbent assay:expression of results as units derived from a standard curve. J Clin Microbiol 1984; 19(4):447-52; PMID:6325495
41. Bishop RF, Bugg HC, Masendycz PJ, Lund JS, Gorrell RJ, Barnes GL. Serum, fecal, and breast milk rotavirus antibodies as indices of infection in mother-infant pairs. J Infect Dis 1996; 174(Suppl 1):S22-9; http://dx.doi.org/10.1093/infdis/174.Supplement_1.S22
42. Coulson BS, Fowler KJ, Bishop RF, Cotton RG. Neutralizing monoclonal antibodies to human rotavirus and indications of antigenic drift among strains from neonates. J Virol 1985; 54(1):14-20; PMID:2579249